Click to Learn More About AtriCure
AtriClip
LAA Exclusion System, the most widely implanted LAA management
Insist on Eliminating the Source!
Don’t Just Manage the Risk,
device globally (30,000+), specifically indicated for LAA exclusion.
Synergy
for the treatment of Persistent
The first and only device approved
and Longstanding Persistent Afib
Invest in the Global Leader
In Afib Solutions
Join Our
World Class Team

AtriCure: Committed to Atrial Fibrillation Treatment and Solutions

AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. In addition, we pioneered the AtriClip®, a left atrial appendage occlusion, device that is the most widely implanted for left atrial appendage management worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.

National News

AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System

10.09.2014
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 365 patients at 40 hospitals across the United States. AtriCure expects to release preliminary data from the study in about a year, with a complete report expected to be published ...

Read More

International News

In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe

10.01.2013
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in this important initiative. This initial course will be led by surgeons recognized as experts in the field of surgical treatment for Afib. They include: James L. Co...

Read More